Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

The usefulness of current psychiatric classification, which is based on ICD/DSM categorical
diagnoses, remains questionable. A promising alternative has been put forward as the …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

Although non‐adherence is common across all branches of medicine, psychotic disorders
pose additional challenges that increase its risk. Despite the importance of non‐adherence …

Background Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs)
versus oral antipsychotics for schizophrenia has been inconsistent across study designs …

BACKGROUND: Preventing relapse is an essential element of early intervention in
psychosis, but relevant risk factors and precise relapse rates remain to be clarified. The aim …

Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia
(HPRL) as a common adverse effect of antipsychotic medication, which remains the …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …